Skip to content

Assessing the optimal amount of tissue sampling in contrast-enhanced biopsy

Assessing the optimal amount of tissue sampling in contrast-enhanced biopsy - CESB

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON55929
Enrollment
150
Registered
2023-09-05
Start date
2023-10-13
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer breast tumor

Interventions

None listed

Sponsors

Zuyderland Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Included women are older than 18 years of age, with a recent finding on CEM requiring CESB (a so-called 'recombined image only lesion' or ROL). Only women able to provide written informed consent will be considered for this study.

Exclusion criteria

Exclusion criteria: Excluded are all men (male sex), and women (female sex) who are contra-indicated for CESB (for example, with impaired renal function or known hypersensitivity reactions to iodinated contrast). Also excluded are pregnant women.

Design outcomes

Primary

MeasureTime frame
The primary study aim will be to calculate the cumulative diagnostic yield per specimen, enabling us to define a minimum number of biopsies required (or tissue volume needed) to establish a reliable diagnosis using CESB.

Secondary

MeasureTime frame
Secondary study outcomes will be general parameters of the biopsy procedure itself, such as patient characteristics, histopathological results, pain experienced during the procedure, and complication rates (hematoma, infection).

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Aug 9, 2026